Related Experiment Video
Updated: Apr 21, 2026

07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.7K
Modest growth seen in epilepsy market
P & T : a Peer-Reviewed Journal for Formulary Management
|November 15, 2014
Summary
The global epilepsy market is growing, projected to reach $5.4 billion by 2022. Pharmaceutical companies are focusing on developing new adjunctive therapies for patients with refractory epilepsy.
Area of Science:
- Neurology
- Pharmaceutical Market Analysis
Background:
- The global epilepsy market generated $4.2 billion in sales in 2012.
- Market growth is projected to reach $5.4 billion by 2022.
- The pharmaceutical landscape for epilepsy is competitive.
Purpose of the Study:
- To analyze the epilepsy market trends.
- To identify pharmaceutical company strategies in the epilepsy sector.
- To understand the focus on adjunctive therapies for refractory epilepsy patients.
Main Methods:
- Market sales data analysis from 2012.
- Projection of market sales to 2022.
- Review of pharmaceutical company strategic shifts.
Main Results:
- Global epilepsy market sales were $4.2 billion in 2012.
- Projected global epilepsy market sales are $5.4 billion by 2022.
- Pharmaceutical companies are prioritizing adjunctive therapies for refractory epilepsy.
Conclusions:
- The epilepsy market demonstrates significant growth potential.
- Strategic focus is shifting towards specialized treatments for refractory epilepsy.
- Development of safe adjunctive therapies is a key area for pharmaceutical innovation.
Related Concept Videos
Epilepsy and Seizures: Overview
1.8K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Epilepsy ll: Types
15
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
15
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Glutamate Antagonists
1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K

